Standard InChI: InChI=1S/C23H20N2O6S/c26-21-18-10-4-6-15-7-5-11-19(20(15)18)22(27)25(21)13-2-1-12-24-32(30,31)17-9-3-8-16(14-17)23(28)29/h3-11,14,24H,1-2,12-13H2,(H,28,29)
1.Patil R, Fells JI, Szabó E, Lim KG, Norman DD, Balogh A, Patil S, Strobos J, Miller DD, Tigyi GJ.. (2014) Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor., 57 (16):[PMID:25100502][10.1021/jm5007116]
2.Bandoh, K K and 5 more authors. 2000-07-28 Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. [PMID:10922489]
3.Kano, Kuniyuki K, Arima, Naoaki N, Ohgami, Mitsuru M and Aoki, Junken J. 2008 LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. [PMID:18781939]
4.Williams, Jesica R JR and 8 more authors. 2009-06-19 Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. [PMID:19366702]
5.Zhang, Honglu H and 10 more authors. 2009-07-01 Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. [PMID:19509223]
6.Fells, James I; Tsukahara, Ryoko; Liu, Jianxiong; Tigyi, Gabor and Parrill, Abby L. 2009-11-01 Structure-based drug design identifies novel LPA3 antagonists. [PMID:19800804]
7.Banerjee, Souvik S and 7 more authors. 2017-02-23 Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells. [PMID:28112925]